MyFinsight
Home
Blog
About
Contact
Net loss
attributable to common...
-$82,958K
Net loss and
comprehensive loss
-$82,958K
Interest income
(expense), net
$4,380K
Loss from operations
-$87,337K
Other income
(expense), net
-$1K
Total operating
expenses
$87,337K
Research and development
$70,047K
General and
administrative
$17,290K
Back
Back
Income Statement
Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc. (EIKN)
source: myfinsight.com